GlassScriptPhysician profile
Michael J Piegari
NPI 1285857714
$4,857.30
in general payments reported to CMS, 2019-2025
36 companies · $812 in 2025
The $812 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $639 · 2021: $906 · 2022: $224 · 2023: $963 · 2024: $527 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.93 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $759.63 | 2021-2025 | V-Loc 180 |
| Abbvie INC. | $455.87 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $450.60 | 2019-2023 | |
| Astellas Pharma US INC | $387.56 | 2023-2025 | Veozah |
| Lupin INC. | $360.81 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $337.46 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $239.54 | 2020-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Mayne Pharma Commercial LLC | $220.49 | 2023 | |
| Exeltis, USA INC. | $219.49 | 2019-2025 | Slynd, Nuvessa |
| Evofem Biosciences, INC. | $180.65 | 2021-2025 | Phexxi, Solosec, Phexx |
| Davol INC. | $177.64 | 2020 | |
| Sage Therapeutics, LLC | $160.55 | 2019-2025 | Zurzuvae |
| Shield Therapeutics INC | $141.13 | 2023-2025 | Accrufer |
| Coopersurgical, INC. | $92.30 | 2023-2025 | Paragard T 380a, Endosee, Advincula Delineator Uterine Manipulator |
| Therapeuticsmd, INC. | $72.25 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $60.21 | 2021-2022 | |
| Organon LLC | $52.75 | 2024-2025 | Nexplanon |
| Applied Medical Resources Corporation | $47.44 | 2024 | |
| Renovia INC | $45.61 | 2019 | |
| Novo Nordisk INC | $42.46 | 2019-2023 | Wegovy, Saxenda |
| Acessa Health INC. | $36.96 | 2019 | |
| Pfizer INC. | $30.76 | 2024 | |
| Allergan, INC. | $29.35 | 2019-2020 | |
| Biogen, INC. | $26.74 | 2024 | Zurzuvae |
| Baxter Healthcare | $25.45 | 2024 | Perclot |
| Aspira Women'S Health INC | $24.65 | 2019-2024 | Ova1 |
| Duchesnay USA Incorporated | $24.11 | 2019 | |
| Merck Sharp & Dohme LLC | $22.49 | 2021 | |
| Meditrina | $20.59 | 2023 | |
| Ortho-Clinical Diagnostics, INC. | $20.22 | 2019 | |
| Medinc of Texas | $19.85 | 2025 | |
| Avion Pharmaceuticals | $18.62 | 2023 | Balcoltra |
| Medicem INC. | $14.93 | 2020 | |
| Olympus America INC. | $14.34 | 2019 | |
| Gynesonics, INC. | $12.97 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Mylan Pharmaceuticals INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Piegari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.